- Email: [email protected]
CARDIOMETABOLIC RISK FACTORS IN TYPE II DIABETIC PATIENTS
224
Publication Only
drogenase, total cholesterol, triglycerides, low density lipoprotein levels in serum and lipid peroxides levels in heart homogenates were observed with a concomitant decrease in myocardial glutathione and serum high density lipoprotein levels in pathogenic control rats as compared to vehicle control rats. Furthermore, aqueous Embelia ribes extract (100 and 200 mg/kg, 30 days) treatment significantly reversed all the above mentioned parameters in dose dependant manner as compared to pathogenic control rats. The results of test drug were comparable to folic acid (100 mg/kg), a standard antihyperhomocysteinemic agent. Conclusion: Aqueous Embelia ribes extract has significant antihyperhomocysteinemic and lipid lowering potential in methionine-induced hyperhomocysteinemia in albino rats. 38
CARDIOMETABOLIC RISK FACTORS IN TYPE II DIABETIC PATIENTS
I.A. Kyriazis 1 , E. Zervas 2 , D. Mytas 3 , A. Diakoumopoulos 2 , G. Christodoulou 2 , A. Lalousis 2 , P. Stougianos 3 , E. Deda 2 , Z. Katsare 2 , P. Klimatsaki 2 , D. Presvelos 2 , Ch. Partheniou 1 . 1 Diabetes Outpatient Clinic, Korinthos General Hospital, Korinthos, Greece; 2 Internal Medicine Dpt., Korinthos General Hospital, Korinthos, Greece; 3 Cardiology Dpt., Korinthos General Hospital, Korinthos, Greece Background and Aims: Diabetes Mellitus (DM) is considered an equivalent of coronary artery disease (CAD). Our aim was to evaluate the prevalence of hypertension, glycemic control, diabetic complications and medical treatment of type 2 diabetic patients (T2DP) with and without dyslipidemia. Materials and Methods: We studied 522 T2DP (238 male/284 female, mean age 60.4±0.8sem years). We assessed their demographic data, blood pressure, lipidemic profile, glucosylated Hb (Hba1c), obesity indices, chronic complications and current medical treatment. Dyslipidemia was defined according to NECP/ATP III revised criteria (2004). Results: Dyslipidemia was present in 330(63.2%)T2DP (Group A), while 192(36.7%) had a normal lipid profile (Group B). Diabetics of Group A had more often hypertension[236(71.5%) vs 102 (53.1%), p<0.01] and especially increased systolic BP (133±18 vs 129±17mmHg, p=0.016), as well as increased waist-hip ratio (0.95±0.09 vs 0.92±0.08, p=0.001). Group A was also more often under antihypertensive treatment (p<0.001), usually with ACE inhibitors. BP control was more difficult in group A and usually required more than one antihypertensive drug (p<0.001). Bigouanids were used more often in group A (p=0,002), while the major hypolipidemic agent was statins in both groups [66.7% in group A vs 2.6% in group B, p<0.001]. Considering the other parameters (age, DM duration, BMI, diastolic BP and HbA1c), there were no statistical differences between the two groups. As for the cardiovascular complications, there was a significant difference regarding CAD (p=0.008). Conclusions: The prevalence of dyslipidemia is substantial among T2DP. Besides, the presence of abdominal obesity is increasingly high among them and they suffer more often from hypertension (mainly systolic). Thus, diabetic dyslipidemic patients demonstrate quite frequent cardiovascular complications such us coronary artery disease. 39
204 comprised the non-obese group B with no age or sex difference among them. Metabolic syndrome (MS) was recorded in 86%(group A) and 40% (group B), p=0.0001. The only statistically significant difference in favor of group A regarded diabetes mellitus (56% in contrast to 26%,p=0.0001). The obese group exhibited higher levels of triglycerides (149±76 vs 123±66 mg/dl,p=0.00001), fasting glucose (151±51 vs 124±40 mg/dl, p=0.001) and waist circumference (112±7cm vs 93.7cm, p=0.0001). A trend in the high density lipoproteins difference levels was observed, yet, it was statistically insignificant. Finally, the obese persons with MS exhibited a higher frequency of in hospital events (by 46.9%) and higher number of readmissions (18%) during the following 6-month period. Conclusions: The prevalence of obesity was observed to be particularly increased among the patients that suffer an ACS. The obese, suffered more frequently by diabetes mellitus and had distorted lipidemic profile, while the additional presence of MS was combined with an increased risk of in hospital events and readmissions. 40
CYSTATIN C LEVELS IN ACUTE CORONARY SYNDROME IS RELATED TO EXTENT OF CORONARY ARTERY DISEASE AND COMPLEXITY OF CORONARY LESION
A. Ozgul, E. Karacaglar, L. Sade, E. Polat, C. Ertan, I. Atar, A. Yildirir, B. Ozin, H. Muderrisoglu. Department of Cardiology, Baskent University Faculty of Medicine, Ankara, Turkey Background and Aims: Cystatin C is a new endogen marker which reflects both renal dysfunction and clinical adverse events associated with coronary artery disease (CAD) and heart failure. However little is known about the relationship between plasma concentration of Cystatin C and the severity of the CAD. Methods: 165 patients admitted with acute coronary syndrome (ACS) (109 M, mean age:62±11) were investigated prospectively. Results: Cystatin C levels did not differ between groups in terms of gender, smoking, hipertension, hyperlipidemia and diabetes. There was a significant positive correlation between levels of cystatin C and extent of CAD in groups called minimal, univessel and multi-vessel CAD (Figure 1). Cystatin C level was significantly higher in patients with Type A lesion than those with Type B and C lesions (Figure 2). We also found that cystatin C level>1.4mg/l was related to TIMI risk score>3 (HR 2.7[95%, 1.2-5.7]; p=0.009).
CARDIOMETABOLIC RISK FACTORS IN PATIENTS SUFFERED FROM ACUTE CORONARY SYNDROME
I.A. Kyriazis 1 , E. Zervas 2 , D. Mytas 3 , A. Diakoumopoulos 2 , G. Christodoulou 2 , P. Stougiannos 3 , A. Lalousis 2 , E. Deda 2 , Z. Katsare 2 , P. Klimatsaki 2 , D. Presvelos 2 , B. Sidachmed 2 , V. Pyrgakis 3 . 1 Obesity & Lipids Outpatient Clinic, Korinthos General Hospital, Korinthos, Greece; 2 Internal Medicine Dpt., Korinthos General Hospital, Korinthos, Greece; 3 Cardiology Dpt., Korinthos General Hospital, Korinthos, Greece Background and Aims: To investigate the prevalence of cardiometabolic risk factors (CMRF) in patients suffered from acute coronary syndrome (ACS) and finally, to evaluate its effect in the short-term prognosis of these patients. Materials and Methods: 261 patients (mean age 64±12years,189 male/72 female) hospitalized due to an ACS, divided into two groups (Group A: BMI>30kgr/m2 , Group B: BMI<30kgr/m2 ). Initially, a detailed medical history was record and the metabolic profile was evaluated. The patients were then evaluated concerning the existence of CMRF. We subsequently compare them with regards to in-hospital complications, cardiac mortality and readmissions in 6 month follow-up. Results: Group A consisted of 57 obese patients (21.8%), while the rest
Conclusions: Serum cystatin C concentrations are associated with the extent and lesion complexity of CAD in ACS. Cystatin C may have clinical promise for risk stratification of patients with ACS. 41
THE ROLE OF ENDOTHELIAL CELL IN THE IMMUNE INFLAMATION INITIATION DURING THE ATHEROSCLEROSIS
Ie.G. Zota, E.M. Melnic, M.I. Untesco. Pathology Department, State University of Medicine and Farmacy, Chisinau, Moldova The aim of this study was to clarify the endothelial cell role in immune inflammation initiating. We studied levels of VCAM-1, eNOS, LDL, IL-1, TNF-α, HSP-60 Ÿi CRP. The study has been performed on the human aorta, coronary, cerebral arteries, collected from early performed autopsies and experimental models of atherosclcerosis in laboratory animals. The role of this molecules has been studied using electronomicroscopic, imunomor-
77th Congress of the European Atherosclerosis Society, April 26–29, 2008, Istanbul, Turkey
Publication Only
drogenase, total cholesterol, triglycerides, low density lipoprotein levels in serum and lipid peroxides levels in heart homogenates were observed with a concomitant decrease in myocardial glutathione and serum high density lipoprotein levels in pathogenic control rats as compared to vehicle control rats. Furthermore, aqueous Embelia ribes extract (100 and 200 mg/kg, 30 days) treatment significantly reversed all the above mentioned parameters in dose dependant manner as compared to pathogenic control rats. The results of test drug were comparable to folic acid (100 mg/kg), a standard antihyperhomocysteinemic agent. Conclusion: Aqueous Embelia ribes extract has significant antihyperhomocysteinemic and lipid lowering potential in methionine-induced hyperhomocysteinemia in albino rats. 38
CARDIOMETABOLIC RISK FACTORS IN TYPE II DIABETIC PATIENTS
I.A. Kyriazis 1 , E. Zervas 2 , D. Mytas 3 , A. Diakoumopoulos 2 , G. Christodoulou 2 , A. Lalousis 2 , P. Stougianos 3 , E. Deda 2 , Z. Katsare 2 , P. Klimatsaki 2 , D. Presvelos 2 , Ch. Partheniou 1 . 1 Diabetes Outpatient Clinic, Korinthos General Hospital, Korinthos, Greece; 2 Internal Medicine Dpt., Korinthos General Hospital, Korinthos, Greece; 3 Cardiology Dpt., Korinthos General Hospital, Korinthos, Greece Background and Aims: Diabetes Mellitus (DM) is considered an equivalent of coronary artery disease (CAD). Our aim was to evaluate the prevalence of hypertension, glycemic control, diabetic complications and medical treatment of type 2 diabetic patients (T2DP) with and without dyslipidemia. Materials and Methods: We studied 522 T2DP (238 male/284 female, mean age 60.4±0.8sem years). We assessed their demographic data, blood pressure, lipidemic profile, glucosylated Hb (Hba1c), obesity indices, chronic complications and current medical treatment. Dyslipidemia was defined according to NECP/ATP III revised criteria (2004). Results: Dyslipidemia was present in 330(63.2%)T2DP (Group A), while 192(36.7%) had a normal lipid profile (Group B). Diabetics of Group A had more often hypertension[236(71.5%) vs 102 (53.1%), p<0.01] and especially increased systolic BP (133±18 vs 129±17mmHg, p=0.016), as well as increased waist-hip ratio (0.95±0.09 vs 0.92±0.08, p=0.001). Group A was also more often under antihypertensive treatment (p<0.001), usually with ACE inhibitors. BP control was more difficult in group A and usually required more than one antihypertensive drug (p<0.001). Bigouanids were used more often in group A (p=0,002), while the major hypolipidemic agent was statins in both groups [66.7% in group A vs 2.6% in group B, p<0.001]. Considering the other parameters (age, DM duration, BMI, diastolic BP and HbA1c), there were no statistical differences between the two groups. As for the cardiovascular complications, there was a significant difference regarding CAD (p=0.008). Conclusions: The prevalence of dyslipidemia is substantial among T2DP. Besides, the presence of abdominal obesity is increasingly high among them and they suffer more often from hypertension (mainly systolic). Thus, diabetic dyslipidemic patients demonstrate quite frequent cardiovascular complications such us coronary artery disease. 39
204 comprised the non-obese group B with no age or sex difference among them. Metabolic syndrome (MS) was recorded in 86%(group A) and 40% (group B), p=0.0001. The only statistically significant difference in favor of group A regarded diabetes mellitus (56% in contrast to 26%,p=0.0001). The obese group exhibited higher levels of triglycerides (149±76 vs 123±66 mg/dl,p=0.00001), fasting glucose (151±51 vs 124±40 mg/dl, p=0.001) and waist circumference (112±7cm vs 93.7cm, p=0.0001). A trend in the high density lipoproteins difference levels was observed, yet, it was statistically insignificant. Finally, the obese persons with MS exhibited a higher frequency of in hospital events (by 46.9%) and higher number of readmissions (18%) during the following 6-month period. Conclusions: The prevalence of obesity was observed to be particularly increased among the patients that suffer an ACS. The obese, suffered more frequently by diabetes mellitus and had distorted lipidemic profile, while the additional presence of MS was combined with an increased risk of in hospital events and readmissions. 40
CYSTATIN C LEVELS IN ACUTE CORONARY SYNDROME IS RELATED TO EXTENT OF CORONARY ARTERY DISEASE AND COMPLEXITY OF CORONARY LESION
A. Ozgul, E. Karacaglar, L. Sade, E. Polat, C. Ertan, I. Atar, A. Yildirir, B. Ozin, H. Muderrisoglu. Department of Cardiology, Baskent University Faculty of Medicine, Ankara, Turkey Background and Aims: Cystatin C is a new endogen marker which reflects both renal dysfunction and clinical adverse events associated with coronary artery disease (CAD) and heart failure. However little is known about the relationship between plasma concentration of Cystatin C and the severity of the CAD. Methods: 165 patients admitted with acute coronary syndrome (ACS) (109 M, mean age:62±11) were investigated prospectively. Results: Cystatin C levels did not differ between groups in terms of gender, smoking, hipertension, hyperlipidemia and diabetes. There was a significant positive correlation between levels of cystatin C and extent of CAD in groups called minimal, univessel and multi-vessel CAD (Figure 1). Cystatin C level was significantly higher in patients with Type A lesion than those with Type B and C lesions (Figure 2). We also found that cystatin C level>1.4mg/l was related to TIMI risk score>3 (HR 2.7[95%, 1.2-5.7]; p=0.009).
CARDIOMETABOLIC RISK FACTORS IN PATIENTS SUFFERED FROM ACUTE CORONARY SYNDROME
I.A. Kyriazis 1 , E. Zervas 2 , D. Mytas 3 , A. Diakoumopoulos 2 , G. Christodoulou 2 , P. Stougiannos 3 , A. Lalousis 2 , E. Deda 2 , Z. Katsare 2 , P. Klimatsaki 2 , D. Presvelos 2 , B. Sidachmed 2 , V. Pyrgakis 3 . 1 Obesity & Lipids Outpatient Clinic, Korinthos General Hospital, Korinthos, Greece; 2 Internal Medicine Dpt., Korinthos General Hospital, Korinthos, Greece; 3 Cardiology Dpt., Korinthos General Hospital, Korinthos, Greece Background and Aims: To investigate the prevalence of cardiometabolic risk factors (CMRF) in patients suffered from acute coronary syndrome (ACS) and finally, to evaluate its effect in the short-term prognosis of these patients. Materials and Methods: 261 patients (mean age 64±12years,189 male/72 female) hospitalized due to an ACS, divided into two groups (Group A: BMI>30kgr/m2 , Group B: BMI<30kgr/m2 ). Initially, a detailed medical history was record and the metabolic profile was evaluated. The patients were then evaluated concerning the existence of CMRF. We subsequently compare them with regards to in-hospital complications, cardiac mortality and readmissions in 6 month follow-up. Results: Group A consisted of 57 obese patients (21.8%), while the rest
Conclusions: Serum cystatin C concentrations are associated with the extent and lesion complexity of CAD in ACS. Cystatin C may have clinical promise for risk stratification of patients with ACS. 41
THE ROLE OF ENDOTHELIAL CELL IN THE IMMUNE INFLAMATION INITIATION DURING THE ATHEROSCLEROSIS
Ie.G. Zota, E.M. Melnic, M.I. Untesco. Pathology Department, State University of Medicine and Farmacy, Chisinau, Moldova The aim of this study was to clarify the endothelial cell role in immune inflammation initiating. We studied levels of VCAM-1, eNOS, LDL, IL-1, TNF-α, HSP-60 Ÿi CRP. The study has been performed on the human aorta, coronary, cerebral arteries, collected from early performed autopsies and experimental models of atherosclcerosis in laboratory animals. The role of this molecules has been studied using electronomicroscopic, imunomor-
77th Congress of the European Atherosclerosis Society, April 26–29, 2008, Istanbul, Turkey